Last reviewed · How we verify
trazodone, pregabalin
trazodone, pregabalin is a Combination anxiolytic/analgesic (serotonin antagonist and reuptake inhibitor + gabapentinoid) Small molecule drug developed by Universidad de Granada. It is currently FDA-approved for Anxiety disorders with concurrent pain or neuropathic pain symptoms. Also known as: Deprax, Lyrica.
This is a fixed-dose combination of trazodone (a serotonin antagonist and reuptake inhibitor) and pregabalin (a gabapentinoid that modulates calcium channels) designed to treat anxiety and pain-related conditions.
Trazodone and pregabalin are medications that have been studied in clinical trials for various conditions, including fibromyalgia, depression, and schizophrenia. Pregabalin is a small molecule that modulates voltage-gated calcium channels, which is its primary mechanism of action.
At a glance
| Generic name | trazodone, pregabalin |
|---|---|
| Also known as | Deprax, Lyrica |
| Sponsor | Universidad de Granada |
| Drug class | Combination anxiolytic/analgesic (serotonin antagonist and reuptake inhibitor + gabapentinoid) |
| Target | 5-HT2A receptor, serotonin transporter (SERT), alpha-2-delta calcium channel subunit |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology (Anxiety, Pain Management) |
| Phase | FDA-approved |
Mechanism of action
Trazodone acts primarily as a serotonin 2A antagonist and serotonin reuptake inhibitor, enhancing serotonergic neurotransmission to reduce anxiety and improve mood. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters and providing anxiolytic and analgesic effects. The combination targets both serotonergic and GABAergic pathways to address anxiety with concurrent pain or neuropathic symptoms.
Approved indications
- Anxiety disorders with concurrent pain or neuropathic pain symptoms
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Headache
- Weight gain
Key clinical trials
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- trazodone, pregabalin CI brief — competitive landscape report
- trazodone, pregabalin updates RSS · CI watch RSS
- Universidad de Granada portfolio CI
Frequently asked questions about trazodone, pregabalin
What is trazodone, pregabalin?
How does trazodone, pregabalin work?
What is trazodone, pregabalin used for?
Who makes trazodone, pregabalin?
Is trazodone, pregabalin also known as anything else?
What drug class is trazodone, pregabalin in?
What development phase is trazodone, pregabalin in?
What are the side effects of trazodone, pregabalin?
What does trazodone, pregabalin target?
Related
- Drug class: All Combination anxiolytic/analgesic (serotonin antagonist and reuptake inhibitor + gabapentinoid) drugs
- Target: All drugs targeting 5-HT2A receptor, serotonin transporter (SERT), alpha-2-delta calcium channel subunit
- Manufacturer: Universidad de Granada — full pipeline
- Therapeutic area: All drugs in Psychiatry/Neurology (Anxiety, Pain Management)
- Indication: Drugs for Anxiety disorders with concurrent pain or neuropathic pain symptoms
- Also known as: Deprax, Lyrica
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing